"Ceara is very happy to help correct regional inequalities. It is the country's time to celebrate because we see investing in Brazil and seeing possibilities," said state governor Cid Gomes.
"Organic products are more effective compared to traditional medicines from chemical synthesis, increasing the chances of successful treatment especially for chronic diseases. They are made from living material and manufactured from processes involving personalized medicine and molecular biology."
"Currently biological resources represent 43% of the medicines used by the Ministry of Health, or about U.S. $ 4 billion per year."
Full text of the original Portuguese language article is available at this link: http://www.jornaldebrasilia.com.br/site/noticia.php?brasil-amplia-producao-de-medicamentos-biologicos&id=476955
About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. Additionally, iBio is developing select product candidates that have been derived from the iBioLaunch platform. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and is designed to significantl
|SOURCE iBio, Inc.|
Copyright©2012 PR Newswire.
All rights reserved